

## Cuvitru

Abu Dhabi · access guide

# How to access Cuvitru for primary immunodeficiency from Abu Dhabi: 2026 pathway via SSMC, CCAD, Tawam, and SKMC allergy-immunology | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Abu Dhabi has the UAE's strongest in-emirate allergy-immunology depth at SSMC, CCAD, Tawam Hospital, SKMC, and Burjeel Medical City. PI patients are diagnosed and managed in-emirate. The 2026 question is whether to convert selected adults and paediatric patients (2+) to weekly self-administered SC Cuvitru under EDE named-patient import.

## Why Cuvitru, why now

Cuvitru is subcutaneous immune globulin 20% for primary humoral immunodeficiency in adults and paediatric patients aged 2 and older. Self-administered weekly. Useful for poor venous access, IVIG wear-off symptoms, or schedule-incompatible monthly infusion.

Reserve Meds does not promote one IgG product over another. Alternatives include Hyqvia, Octagam, Gammagard, Privigen, and others.

## What Cuvitru is, in plain language

20% IgG liquid injected under the skin at abdomen or thigh, once weekly. Self-administered at home after training. Pump-driven 60-90 minutes. Steady-state IgG after several weeks.

## Eligibility at an Abu Dhabi allergy-immunology clinic

Required: confirmed PI with documented IgG deficiency, impaired specific antibody response, or genetic confirmation. Self-administration capability. IgG trough goal established.

## The Abu Dhabi prescribing and supply picture

Cuvitru is not currently EDE-registered. Access via EDE-approved named-patient import filed through SSMC, CCAD, Tawam, SKMC, or Burjeel Medical City pharmacy with DoH Abu Dhabi acknowledgment. Cold chain required. Reserve Meds coordinates the import file, prescription chain, and shipping.

## Cost band

---

USD 75K-110K annual per patient (AED 275K-405K), weight-and-dose dependent. Thiqa for Emirati nationals may cover under rare-disease provision; Daman Enhanced and private payors cover IVIG/SCIG with pre-authorisation.

## What to expect, week-by-week

---

Weeks 0 to 2: EDE import filing, prescription, training arrangement. Weeks 2 to 4: shipment arrives, clinic-supervised SC training. Weeks 4 to 16: weekly SC at home; IgG trough at week 12. Month 6 and 12: full reassessment, infection log review, dose adjustment.

## When Cuvitru is the wrong drug

---

Good venous access and no self-injection appetite: IVIG. Unable to reliably self-administer: IVIG safer. Hard to achieve trough weekly: consider larger less-frequent SC dosing (competing product). Reserve Meds does not promote one IgG over another.

## Closing

---

Reserve Meds runs the Cuvitru import file from the SSMC, CCAD, Tawam, or SKMC allergy-immunology referral through EDE named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist.

### ***Reserve Meds's role***

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com